Global Partners LP Stock News

GLP-1 drugs have put peptides on investors' radar, with Eli Lilly (LLY) and Novo Nordisk (NVO) leading the weight-loss market. But the investment opportunity extends beyond these treatments.

A new peptide ETF launched today, holding the drugmakers behind GLP-1 weight-loss treatments along with the companies that make and deliver them. Key Takeaways: REX's new fund follows 36 peptide-linked companies, ranging from GLP-1 drugmakers to device and supplement makers.

Rapid weight loss can lead to issues with bone quality, particularly in older adults.

The NBI Thematic Rotation ETF (NTHM:TSX) has completed its latest portfolio rebalance, pivoting away from broad tech and industrial momentum to channel capital into midstream energy infrastructure and GLP-1 weight-loss drug manufacturers. The fund tracks the Thematic Rotation Quality Momentum Screened Index (TRQMS).

NEWTON, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) today reported financial results for the second quarter ended June 30, 2026. CEO Commentary “The second quarter was marked by strong contributions in all of our segments, with our business executing well in a dynamic market environment,” said Eric Slifka, the Partnership's President and Chief Executive Officer. “The breadth of our l...

NEWTON, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that its 2025 Schedule K-3 reflecting items of international tax relevance is available online. Unitholders requiring this information may access their Schedule K-3 at www.taxpackagesupport.com/globalpartners. A limited number of unitholders (primarily foreign unitholders, uni...

The midstream energy sector continues to demonstrate its commitment to returning capital to shareholders. Major energy infrastructure companies recently announced sequential increases in payouts during Q3 2026, bolstering income generation across the space.